$TirzepatidePriceGuide
Best for · flat rate

Best flat-rate tirzepatide

What to look for, and the program we pick for this need.

Released: · Last reviewed:

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 10, 2026 · This page is informational and does not constitute medical advice.

Our pick for flat-rate compounded tirzepatide is NexLife, which charges the same price at every dose: $129 month to month or $115 a month on a 12-month plan (as of November 6, 2026); Eden ($129 every month) and Collective ($69 plus a $199 yearly membership) also print one price at any dose.

Flat pricing matters most if you expect to reach 10 mg or 15 mg. Compounded tirzepatide is not FDA-approved.

Flat-rate programs compared

Programs that print one price at every dose. NexLife as of November 6, 2026; others read October 15, 2026.
ProgramPriceDose policyNotes
NexLife$129 month to month; $115 on 12 monthsSame at every doseNo membership; three 503A pharmacies named
Eden$129 every monthSame every monthNo membership fees
Collective$69 + $199 a year (about $86)"Same price, any dose"Membership billed yearly
Our top pick · 94/100 on methodology v4.1

NexLife

$129 month to month, or $115 a month on a 12-month plan ($1,380 a year), the same price at every dose, with no membership (as of November 6, 2026). Plans of 3 and 6 months are $125 and $119 a month.

Included, per NexLife's plan pages: provider review and medical guidance (NexLife Medical Group), a personalized nutrition plan, a 1:1 call with a wellness coach, 24/7 support and free expedited shipping. The plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).

Not the lowest price we track. Compounded tirzepatide is not FDA-approved; a licensed clinician decides whether it is right for you.

See NexLife's current plans → Read the review
FAQ

Questions readers ask

Does compounded tirzepatide cost more at higher doses?

It depends on the program. Flat-rate programs such as NexLife, Eden and Collective charge one price from 2.5 mg to 15 mg. Per-dose programs climb as you step up: Emerge lists $224 per 4 weeks at 2.5 mg and $289 at 15 mg (read October 15, 2026). Ask for the price at your maintenance dose before you enroll.

Is NexLife the cheapest option?

No. As of November 6, 2026, NexLife charges $129 month to month and $115 a month on a 12-month plan. In our index, Collective (with its yearly membership), WellMedr (on sale) and Mondae (prepaid 6 months) show lower all-in figures, and Eden matches NexLife's $129 month to month. We rank NexLife first on our full methodology, not on price alone.

What does all-in monthly price mean?

It is the medication price plus any required membership or program fee, with yearly fees divided by 12. Collective's $69 a month plus a $199 yearly membership comes to about $86 a month; IVIM Health's $117 starting price plus a $75 monthly program fee comes to $192. All-in figures let you compare programs with and without memberships.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold. It is made with the drug in Zepbound and Mounjaro, but it is not the same product. Lilly's Zepbound and Mounjaro are the FDA-approved tirzepatide medicines.

Sources

  1. NexLife, compounded tirzepatide plans, read November 6, 2026.
  2. Eden, GLP-1 weight loss pricing, read October 15, 2026.
  3. Collective, holistic weight loss pricing, read October 15, 2026.
  4. Emerge Weight Loss, pricing, read October 15, 2026.
  5. Eli Lilly, Zepbound coverage and self-pay savings, read October 15, 2026.
  6. FDA, Concerns with unapproved GLP-1 drugs used for weight loss, page current as of October 1, 2026.

Full program list with links: price index and the open dataset tirzepatide-price-index.json (CC BY 4.0).